AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Stock Down 0.8 %

Shares of NYSE:ABBV opened at $141.44 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. The stock has a fifty day simple moving average of $146.52 and a two-hundred day simple moving average of $150.47. AbbVie has a 12-month low of $105.56 and a 12-month high of $175.91. The stock has a market capitalization of $250.08 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 3.99 and a beta of 0.70.

AbbVie (NYSE:ABBV - Get Rating) last posted its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.42 by $0.09. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. The firm had revenue of $14.58 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same quarter in the previous year, the firm earned $3.11 EPS. AbbVie's quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 15th. Stockholders of record on Friday, July 15th were issued a dividend of $1.41 per share. This represents a $5.64 dividend on an annualized basis and a dividend yield of 3.99%. The ex-dividend date of this dividend was Thursday, July 14th. AbbVie's payout ratio is 79.89%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their price target on AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. Barclays decreased their target price on AbbVie to $160.00 in a report on Tuesday, August 9th. SVB Leerink initiated coverage on shares of AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 price target on the stock. Piper Sandler decreased their price objective on shares of AbbVie from $160.00 to $155.00 in a report on Friday, July 29th. Finally, UBS Group cut their target price on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating on the stock in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average price target of $159.63.

Insider Activity at AbbVie

In other AbbVie news, Vice Chairman Michael Severino sold 79,801 shares of the stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the sale, the insider now directly owns 152,103 shares in the company, valued at approximately $22,952,342.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.08% of the stock is owned by insiders.